Results for:(11 found)
Nov 26, 2013 11:55AM on Top StocksBy Forbes Digital

So far, 2 leading treatments have fizzled. But Orexigen hopes for more success with its new Contrave.

Nov 6, 2013 8:55PM on Top StocksBy Traders Reserve

Companies in diabetes treatment, weight management and weight-loss drugs could see see huge growth.

Jan 4, 2013 12:36PM on Top StocksBy MSN Money Partner

Under Armour is upgraded to 'outperform,' and First Solar is downgraded to 'underperform.'

Nov 9, 2012 2:13PM on Top StocksBy Minyanville.com

Vivus shares dropped after it reported weaker-than-expected sales of its weight loss drug.

Oct 9, 2012 12:59PM on Top StocksBy Minyanville.com

Analyst predicts it will take time, however, before Qsymia records meaningful revenue.

Oct 5, 2012 10:27AM on Top StocksBy InvestorPlace

Companies are trying to use America's weight to their advantage.

Aug 9, 2012 3:02PM on Top StocksBy Minyanville.com

An analyst says the weight-loss drug Qsymia can't live up to investors' expectations.

Jul 18, 2012 11:28AM on Top StocksBy Minyanville.com

Vivus becomes the second pharma this year approved to sell a weight-loss treatment.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.